- Joined
- Nov 5, 2009
- Messages
- 14,210
- Reason
- Lost a loved one
- Diagnosis
- 00/0000
- Country
- US
- State
- WA
- City
- Seattle
Project ALS announced today that the Food and Drug Administration (FDA) has granted orphan drug designation to prosetin for the treatment of ALS. Prosetin is an oral, brain penetrant MAP4 kinase inhibitor developed by scientists at Columbia University for the treatment of ALS. Project ALS funded prosetin’s preclinical development and is sponsoring its translational and potential clinical development.